



TIRZEPATIDE – WITHDRAWAL OF LCS

Sheffield LMC have been informed by SYICB of the withdrawal of the Tirzepatide LCS offer to practices for 26/27 **unless** they have already signed up in 25/26. Their argument is that payment is now covered by the new QoF obesity indicators (OB004 and OB005), worth a total of 18 points.

We note that QoF is a **voluntary** outcomes framework rather than a commissioning vehicle and the presence of an LCS confirms Tirzepatide management is not part of the core contract.

The SYICB commissioning decision creates a two-tier system whereby those signed up to the LCS **will** receive greater reimbursement, and as they are operating under a commissioned arrangement, be covered by CNSGP, whilst those managing Tirzepatide outside the LCS **may not** be covered by CNSGP as they have no contract to manage the drug.

The business rules for QoF indicators OB004 and OB005 allow for personal care adjustments (formally exception reporting) where an appropriate commissioned service is not locally available.